Longterm outcomes and damage accrual in patients with childhood systemic lupus erythematosus with psychosis and severe cognitive dysfunction

Journal of Rheumatology

Volumn 40, Issue 4, 2013, Pages 513-519

  Lim, Lily Siok Hoon ^a   Lefebvre, Arlette ^a   Benseler, Susanne ^a   Silverman, Earl D ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cognitive dysfunction; Damage; Outcome; Pediatric; Psychiatric; Psychosis; Systemic lupus erythematosus

Indexed keywords

ANTIDEPRESSANT AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROLEPTIC AGENT; PREDNISONE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL EVALUATION; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; REMISSION; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE;

AZATHIOPRINE; COGNITION DISORDERS; COHORT STUDIES; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS; PSYCHOTIC DISORDERS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84875865468     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121096     Document Type: Article

References (25)

1. Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007;16:564-71.
2. Harel L, Sandborg C, Lee T, von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006;33:1873-7.
3. Olfat MO, Al-Mayouf SM, Muzaffer MA. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004;23:395-9.
4. Sibbitt WL Jr, Brandt JR, Johnson CR, Maldonado ME, Patel SR, Ford CC, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002;29:1536-42.
5. Yu HH, Lee JH, Wang LC, Yang YH, Chiang BL. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: A 20-year study. Lupus 2006;15:651-7.
6. Steinlin MI, Blaser SI, Gilday DL, Eddy AA, Logan WJ, Laxer RM, et al. Neurologic manifestations of pediatric systemic lupus erythematosus. Pediatr Neurol 1995;13:191-7.
7. Yancey CL, Doughty RA, Athreya BH. Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum 1981;24:1389-95.
8. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
9. Muscal E, Nadeem T, Li X, Mian A, Harris TB. Evaluation and treatment of acute psychosis in children with systemic lupus erythematosus (SLE): Consultation-liaison service experiences at a tertiary-care pediatric institution. Psychosomatics 2010;51:508-14.
10. Turkel SB, Miller JH, Reiff A. Case series: Neuropsychiatric symptoms with pediatric systemic lupus erythematosus. J Am Acad Child Adolesc Psychiatry 2001;40:482-5.
11. Brunner HI, Ruth NM, German A, Nelson S, Passo MH, Roebuck-Spencer T, et al. Initial validation of the Pediatric Automated Neuropsychological Assessment Metrics for childhood-onset systemic lupus erythematosus. Arthritis Rheum 2007;57:1174-82.
12. Lim LSH, Lefebvre A, Benseler S, Peralta M, Silverman E. Psychiatric illness of systemic lupus erythematosus in childhood: spectrum of clinically important manifestations. J Rheumatol 2012; Dec 15 (E-pub ahead of print).
13. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9.
14. Gutierrez-Suarez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006;54:2989-96.
15. Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006;15:515-20.
16. Ravelli A, Duarte-Salazar C, Buratti S, Reiff A, Bernstein B, Maldonado-Velazquez MR, et al. Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. Arthritis Rheum 2003;49:501-7.
17. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002;46:436-44.
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
19. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
20. Denburg SD, Carbotte RM, Denburg JA. Psychological aspects of systemic lupus erythematosus: Cognitive function, mood, and self-report. J Rheumatol 1997;24:998-1003.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
22. Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
23. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. Systemic Lupus International Collaborative Clinics: Development of a damage index in systemic lupus erythematosus. J Rheumatol 1992;19:1820-1.
24. Baca V, Lavalle C, Garcia R, Catalan T, Sauceda JM, Sanchez G, et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999;26:432-9.
25. Pego-Reigosa JM, Isenberg DA. Psychosis due to systemic lupus erythematosus: Characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology 2008;47:1498-502.